HCM
BCAB icon

Highbridge Capital Management’s BioAtla BCAB Stock Holding History

Highbridge Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,193
Closed -$1.48M – 257
2024
Q4 		$1.48M Buy
+50,193
New +$4.21M 0.06% 121

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Highbridge Capital Management's BCAB Position: Q1 2025 in Review

Highbridge Capital Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 50,193 shares — an estimated $1.48M sold.

Highbridge Capital Management first reported a position in BCAB in Q4 2024 and held it in 1 quarter. The position peaked at $1.48M in Q4 2024. 42 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

  • Highbridge Capital Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 50,193 BioAtla shares in Q1 2025, an estimated $1.48M.
  • Highbridge Capital Management first reported a position in BioAtla in Q4 2024 and held it in 1 quarter.
  • Highbridge Capital Management's BioAtla position peaked at $1.48M in Q4 2024.
  • 42 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.